

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

Attorney Docket No.: 021167-000000US

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

On October 31, 2003

TOWNSEND and TOWNSEND and CREW LLP

By: Kathryn A. Degliantoni

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Robert F. Balint, et al.

Application No.: 09/526,106

Filed: March 15, 2000

For: INTERACTION-ACTIVATED
PROTEINS

Examiner: Epperson, Jon D.

Art Unit: 1639

SUPPLEMENTAL INFORMATION
DISCLOSURE STATEMENT UNDER 37
CFR §1.97 and §1.98

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450


11/04/2003 HGUTEMA1 00000104 201430 09526106
01 FC:1806 180.00 DA

Sir:

The references cited on attached form PTO/SB/08A and PTO/SB/08B were cited in an Information Disclosure Statement on November 29, 2000 and were rejected by the Examiner in the Office Action dated September 23, 2003, for not having titles of the references listed. Because copies of the references were included the IDS mailed November 29, 2000, the references are not enclosed.

It is respectfully requested that the cited references be expressly considered during the prosecution of this application, and the references be made of record therein and appear among the "references cited" on any patent to issue therefrom.

As provided for by 37 CFR 1.97(g) and (h), no inference should be made that the information and references cited are prior art merely because they are in this statement and no




representation is being made that a search has been conducted or that this statement encompasses all the possible relevant information.

This IDS is being filed before the mailing date of the final Office Action or Notice of Allowance.

Please charge the IDS fee of \$180 to Deposit Account No. 20-1430. Please deduct any additional fees from, or credit any overpayment to, the above-noted Deposit Account.

Respectfully submitted,

A handwritten signature in black ink, appearing to read "Kenneth E. Jenkins".

Kenneth E. Jenkins, Ph.D.
Reg. No. 51,846

TOWNSEND and TOWNSEND and CREW LLP
Two Embarcadero Center, 8th Floor
San Francisco, California 94111-3834
Tel: 415-576-0200
Fax: 415-576-0300
KEJ:kad

NOV 03 2003

PTO/SB/08B (08-03)

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	09/526,106
				Filing Date	March 15, 2000
				First Named Inventor	Balint, Robert F.
				Art Unit	1639
				Examiner Name	Epperson, Jon D.
Sheet	3	of	3	Attorney Docket Number	021167-000700US

U.S. PATENT DOCUMENTS+					
Examiner Initials*	Cite No. ¹	Document Number Number Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		US-			
		US-			

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. ¹	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³	Number ⁴	Kind Code ⁵ (if known)				
								<input type="checkbox"/>
								<input type="checkbox"/>

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	C1	Rossi, <i>et al.</i> , "Monitoring protein-protein interactions in intact eukaryotic cells by β -galactosidase complementation," <i>Proc Natl Acad Sci.</i> , 94:8405-8410 (8/1997)	
	C2	Pelletier, <i>et al.</i> , "Oligomerization domain-directed reassembly of active dihydrofolate reductase from rationally designed fragments," <i>Proc Natl Acad Sci.</i> , 95:12141-12146 (10/1998)	
	C3	Pelletier, <i>et al.</i> , "A protein complementation assay for detection of protein-protein interactions <i>in vivo</i> ," <i>Protein Engineering</i> , XP-002064563, 10:89 (1997)	
	C4	Johnsson, <i>et al.</i> , "Split ubiquitin as a sensor of protein interactions <i>in vivo</i> ," <i>Proc Natl Acad Sci.</i> , 91:10340-10344 (1994)	
	C5	Karimova, <i>et al.</i> , "A bacterial two-hybrid system based on a reconstituted signal transduction pathway," <i>Proc Natl Acad Sci.</i> , 95:5752-5756 (5/1998)	
	C6	Krebber, <i>et al.</i> , "Reliable cloning of functional antibody variable domains from hybridomas and spleen cell repertoires employing a reengineered phage display system," <i>J. Immunol. Methods</i> , 201:35-55 (1997)	
	C7	Krebber, <i>et al.</i> , "Selectively-infective phage (SIP): A mechanistic dissection of a novel <i>in vivo</i> selection for protein-ligand interactions," <i>J. Mol Biol.</i> , 268:607-618 (1997)	

RECEIVED
NOV 10 2003
TECH CENTER 1600/2900

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.